Search Legislation

The Medicines for Human Use (Clinical Trials) Regulations 2004

 Help about what version

What Version

  • Latest available (Revised)
  • Original (As made)
 Help about advanced features

Advanced Features

 Help about opening options

Opening OptionsExpand opening options

Changes over time for: Paragraph 2

 Help about opening options

Alternative versions:

Changes to legislation:

The Medicines for Human Use (Clinical Trials) Regulations 2004, Paragraph 2 is up to date with all changes known to be in force on or before 27 February 2025. There are changes that may be brought into force at a future date. Changes that have been made appear in the content and are referenced with annotations. Help about Changes to Legislation

[F1List of countries where a sponsor of a clinical trial, or their legal representative, may be established on IP completion day (regulation 3(11A))U.K.

2.(1) For the purpose of regulation 3, the licensing authority must include each EEA State in the list referred to in paragraph (11A) of that regulation.

(2) Notwithstanding regulation 3(11C), the licensing authority must not, before the end of the transitional period, remove an EEA State from the list referred to in regulation 3(11A).

(3) In this paragraph, “transitional period” is the period of two years beginning with IP completion day.]

Back to top

Options/Help